Clinical Data Another LAG-3 setback as Regeneron drug fails phase 3 trial PharmaphorumRegeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.OncologyRead full story pharminent May 18, 2026 (Last updated: May 21, 2026) Pharmaphorum Regeneron’s LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studiesNext: Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
